论文部分内容阅读
目的观察吉西他滨(商品名:健择)与奥沙利铂(GO方案)联合治疗晚期非小细胞肺癌(NSCLC)临床疗效及无进展生存期。方法采用GO方案治疗NSCLC 38例,男25例,女13例,吉西他滨1000mg/m2,静脉滴注,第1、8天,奥沙利铂130mg/m2,静脉滴注,第1天。21d为1周期,治疗至少2个周期。结果完全缓解(CR)3例;部分缓解(PR)12例,稳定(SD)16例,进展(PD)3例,总有效率47.22%。平均无疾病进展生存期(PFS)为6.38个月,主要不良反应为骨髓抑制。结论吉西他滨与奥沙利铂联合治疗晚期非小细胞肺癌(NSCLC)疗效肯定,不良反应轻,可提高局部控制率和1年生存率。
Objective To observe the clinical efficacy and progression-free survival of patients with advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (trade name: Gemz) and oxaliplatin (GO). Methods 38 cases of NSCLC were treated with GO regimen. There were 25 males and 13 females. Gemcitabine 1000 mg/m2 was intravenously administered. On the 1st and 8th days, oxaliplatin 130 mg/m2 was intravenously administered on the first day. 21d is 1 cycle, treatment for at least 2 cycles. Results There were 3 cases of complete remission (CR), 12 cases of partial remission (PR), 16 cases of stable (SD), and 3 cases of progressive (PD). The total effective rate was 47.22%. The mean progression-free survival (PFS) was 6.38 months and the major adverse reaction was myelosuppression. Conclusion The combination of gemcitabine and oxaliplatin is effective in the treatment of advanced non-small cell lung cancer (NSCLC). The adverse reaction is mild, and the local control rate and 1-year survival rate can be improved.